Cannara Biotech Inc. (LOVE.TO) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-112.9%

-CA$0.26

vs CA$2.02 price

Levered DCF

CA$3.93

After debt service

Piotroski score

7 / 9

Strong

Altman Z-score

2.95

Grey zone

Rating

A-

Overall 4 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	12.86×	9.51×	12.85×	51.33×	-42.08×	-5×	-7.75×	-87.9×
P/B	1.63×	0.7×	1.12×	1.77×	2.03×	1.77×	2.32×	14.35×
P/S	1.55×	0.75×	1.56×	3.3×	7.64×	26.57×	52.24×	489.13×
EV / EBITDA	6.8×	6.79×	8.29×	19.71×	30.84×	-7.97×	-8.85×	-126.01×
Gross margin	44.0%	36.4%	47.6%	46.7%	69.7%	48.0%	80.7%	36.8%
Operating margin	20.7%	12.3%	20.8%	12.2%	10.7%	-467.7%	-487.5%	-420.0%
Net margin	12.2%	7.9%	12.1%	6.4%	-9.0%	-541.3%	-659.4%	-556.7%
Current ratio	2.4×	2.5×	2.44×	3.46×	2.82×	3.03×	5.47×	11.59×
Debt / equity	0.41×	0.55×	0.57×	0.73×	0.33×	0.34×	0.28×	0.88×
Interest coverage	5.1×	1.78×	2.24×	1.32×	1.06×	-8.75×	-6.67×	-5.68×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	12.8%	7.3%	8.7%	3.5%	-2.4%	-36.0%	-29.3%	-16.3%
Return on invested capital	10.9%	7.3%	9.4%	3.8%	2.1%	-23.0%	-16.2%	-6.5%
Return on assets	7.8%	4.2%	4.9%	1.8%	-1.7%	-25.2%	-20.3%	-8.3%
Free cash flow yield	8.2%	5.2%	-4.4%	-18.2%	-25.5%	-26.8%	-27.1%	-7.6%
Earnings yield	7.9%	10.5%	7.8%	1.9%	-1.2%	-20.4%	-12.6%	-1.1%
Enterprise value	CA$193.5M	CA$103M	CA$130.8M	CA$154.6M	CA$142.8M	CA$72.9M	CA$96.3M	CA$211.7M
Net debt / EBITDA	0.96×	2.75×	2.63×	4.62×	2.75×	-0.56×	1.22×	-0.08×
Cash conversion cycle (days)	251	326	370	273	145	-97	-3,865	-1,449